Patient Nanyanyiso Baloi holds her treatment regimen for pre-XDR-TB, which includes delamanid and bedaquiline. Khayelitsha, Western Cape.
All Topics

Drug-resistant TB

 
MSF, Doctors Without Borders, Bedaqueline
Multi-drug Resistant Tuberculosis

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits

Press Release 26 Apr 2023
 
MSF, Doctors Without Borders, India rejects Johnson & Johnson patent extension attempt
Drug-resistant TB

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

Press Release 23 Mar 2023
 
MSF, Doctors without Borders, DR-TB Patients in Berbera Hospital, Somaliland
Tuberculosis

TB Patient Education & Counselling Flipchart

Toolkit 22 Feb 2023
 
MSF nurses provides HIV Counselling, Testing and Treatment to a farm worker in Eshowe, KwaZulu-Natal
HIV/AIDS

Patient Support, Education and Counselling Guideline

Guideline 21 Feb 2023
 
Simphiwe holds his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which Simphiwe is taking for the first time today.
Drug-resistant TB

MSF response: WHO announces positive change to TB treatment guidelines

Press Release 4 May 2022
 
TB diagnosis in Tajikstan
Tuberculosis

MSF responds to updated WHO guidelines for tuberculosis in children

Press Release 25 Mar 2022